2007 - 2008 Investigation of the targeted therapy for cancer stem cells
2005 - 2006 アポトーシス抑制分子FLIPの新規機能解析
Show all
Papers (94):
Shun Morino, Tetsuo Mashima, Fumiyuki Shirai, Satoshi Nagayama, Ryohei Katayama, Hiroyuki Seimiya. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer. Cancer letters. 2024. 584. 216632-216632
Mingjue Chen, Tetsuo Mashima, Taichi Oishi, Yukiko Muramatsu, Yosuke Seto, Manabu Takamatsu, Naomi Kawata, Shun Morino, Ayane Nakamura, Saori Inaba, et al. APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. British journal of cancer. 2023
Nobuyuki Kondo, Takahiro Utsumi, Yuki Shimizu, Ai Takemoto, Tomoko Oh-Hara, Ken Uchibori, Sophia Subat-Motoshi, Hironori Ninomiya, Kengo Takeuchi, Makoto Nishio, et al. MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGF. JCI insight. 2023
Tatsuya Yoshida, Toru Kumagai, Ryo Toyozawa, Ryohei Katayama, Makoto Nishio, Takashi Seto, Koichi Goto, Nobuyuki Yamamoto, Yuichiro Ohe, Kentarou Kudou, et al. Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial. Cancer science. 2023. 114. 9. 3698-3707
Mizuki Haraguchi, Kazuma Kiyotani, Tomohiro Tate, Seiji Sakata, Ray Sagawa, Satoshi Takagi, Satoshi Nagayama, Kengo Takeuchi, Kazuhisa Takahashi, Ryohei Katayama. Spatiotemporal commonality of the TCR repertoire in a T-cell memory murine model and in metastatic human colorectal cancer. Cancer immunology, immunotherapy : CII. 2023. 72. 9. 2971-2989
Bo Gong, Kazuma Kiyotani, Seiji Sakata, Ken Takahashi, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, et al. Identification of secreted PD-L1 variants as a decoy of PD-L1 blockade antibody mediating the therapeutic resistance. MOLECULAR CANCER THERAPEUTICS. 2019. 18. 12
Koutaroh Okada, Mitsugu Araki, Tomoko Oh-hara, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama. Predication of lorlatinib resistance mechanisms and therapeutic strategies to overcome the resistance in ALK rearranged non-small cell lung cancer. MOLECULAR CANCER THERAPEUTICS. 2019. 18. 12